NBS >> $2 12 MONTH TARGET SEE HERE PLAYAZZZ

Investment Highlights

Divested ownership interest in Suzhou Erye Pharmaceutical Co, increasing its cash position by $12,280,000 - Already received $1,228,000 (10%)

Acute Myocardial Infarction (AMI) therapeutic product development team enrolled the first patient in the PreSERVE Phase 2 clinical trial

Our Progenitor Cell Therapy (PCT) CDMO service business continues to grow and has added new clients in later stage clinical trials setting the stage for expansion into larger and substantially more lucrative commercial manufacturing contracts

Jonathan Sackner-Bernstein, MD, FACC joined the Company. He was Associate Center Director for Technology and Innovation at the U.S. Food and Drug Administration's Center for Devices and Radiological Health

Actively pursuing additional strategic relationships with major pharmaceutical and biotechnology companies in 2012

WBB Securities LLC - UPGRADED TO STRONG BUY - $2.00 12 MONTH TARGET